A Phase 3 interventional study of Abatacept and Adalimumab in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 84 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-04.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 26 in phase 3, and was the 22nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 869 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2009, is one of 22 in phase 3, and was the 26th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Abatacept
Drug: Adalimumab
Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
Also known as: Orencia, BMS-188667
Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
Also known as: Humira
The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population
Proportion(%)=number of participants meeting criteria (n) divided by number of participants who received drug (N). The ACR score indicates degree of improvement in a patient's rheumatoid arthritis (RA), based on guidelines set forth by the ACR and represents a percentage. To qualify a ACR20 score, patient must have \>=20% fewer tender joints and \>=20% fewer swollen joints and show 20% improvement from baseline in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein (CRP) test (to assess inflammation). Baseline was Day 1. Randomization was stratified using screening Disease Activity Score-28 (DAS28) CRP, a composite of 4 variables: number of tender joints/28, number of swollen joints/28, CRP in mg/L and participant assessment of disease activity with visual analogue scale.
Time frame: Day 1 to Day 365
Proportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population
n=number of participants with a pre-specified local injection site reaction event, N=number of participants at risk. Proportion (%) = n/N. 12 Months includes data up to 56 days post last dose of the first 12 months Period or start of the first dose of second 12 months period.
Time frame: Day 1 to 12 Months
Incidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population
Incidence Rate: (incidence/100 person-years) = number of participants with event \* 100 /exposure (person-years) Exposure (person-years) = the sum over all participants of the exposure per participant in the 24 months (censored at the time of first occurrence of AE) expressed in days, divided by 365.25. The 24 Month Period includes data up to 56 days post the last dose in the 24 month period. Poisson distribution used to construct the 95% CIs.
Time frame: Day 1 to Day 729
Proportion of Participants Without Radiographic Progression in Total Score Less Than or Equal to the Smallest Detectable Change (SDC) From Baseline to Months 12 and 24 Using Modified Van Der Heijde Total Sharp Score (mSvdHS) - ITT Population
Plain radiographs of hands and feet taken at baseline (BL), Day 365, and Day 729. BL and Day 365 radiographs were re-read concurrent with Day 729 films by readers blinded to sequence and treatment (a second pre-specified reading campaign). SDC defined as amount of change for which anything smaller could not be reliably distinguished from random error in measurement of simultaneously read films. Non-progression defined: change from BL (Day 1, prior to dosing) in total score less than, equal to (\<=) SDC(2.2). Proportion n/m (%)=number meeting criteria (n); number analyzed (m). SDC calculated as SD/sqrt(2)\*1.96/sqrt(2)with standard deviation (SD) of paired differences of change from BL in total score between 2 readers; squared root(sqrt). mSvdHS=summary of erosion severity in 32 hand and 12 foot joints. Hand joints scored 0 to 5; foot joints 0 to 10 with 0=no erosion and higher numbers indicating greater erosion severity. BL: radiographic data within 14 days or less of first dose.
Time frame: Baseline to Day 729
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 12 Months of Treatment - ITT Population
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post-last dose of first 12 months or start of first dose of second 12 months); denominator was overall total exposure (person-years) within this period, calculated as sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Day 1 to Day 365
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 24 Months of Treatment - ITT Population
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, and all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post the last dose of the 24 Months period); denominator was overall total exposure (person-years) within this period, which was calculated as the sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express the rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Day 1 to Day 729
Proportion of Participants With Induction of Autoantibodies During the 12 Months and 24 Months Periods - ITT Population
The induction of autoantibodies was defined as participant's antinuclear antibodies (ANA) or anti-double stranded deoxyribonucleic acid (dsDNA) converting from a negative status at baseline to a positive status at a post-baseline measurement time point (Day 365 or Day 729). Proportion (%) = n/m, where n=number of participants with positive ANA or dsDNA at a time point and m=number of participants who had negative ANA or dsDNA at baseline. Blood samples were first tested for ANA by indirect fluorescent assay using HEp-2 Cell Line Substrate, and when positive, samples were further tested for anti-dsDNA by indirect fluorescent assay using Crithidia Luciliae Substrate.
Time frame: Day 1 to Day 729
28-October-2009 to 23-November-2012. Study conducted in biologic-naive participants with Rheumatoid Arthritis (RA) who have failed on methotrexate therapy.
| Milestone | 125 mg Abatacept SC Weekly | 40 mg Adalimumab SC Biweekly |
|---|---|---|
| Started | 318 | 328 |
| Completed | 252 | 245 |
| Not completed | 66 | 83 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Adverse event | 11 | 30 |
| Withdrew: Lack of efficacy | 19 | 16 |
| Withdrew: Lost to follow-up | 7 | 12 |
| Withdrew: Withdrawal by subject | 20 | 9 |
| Withdrew: No longer met criteria | 2 | 1 |
| Withdrew: Poor or non-compliance | 3 | 3 |
| Withdrew: Pregnancy | 0 | 3 |
| Withdrew: Administrative reason by sponsor | 1 | 1 |
| Withdrew: Non-specified | 2 | 7 |
Proportion(%)=number of participants meeting criteria (n) divided by number of participants who received drug (N). The ACR score indicates degree of improvement in a patient's rheumatoid arthritis (RA), based on guidelines set forth by the ACR and represents a percentage. To qualify a ACR20 score, patient must have \>=20% fewer tender joints and \>=20% fewer swollen joints and show 20% improvement from baseline in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein (CRP) test (to assess inflammation). Baseline was Day 1. Randomization was stratified using screening Disease Activity Score-28 (DAS28) CRP, a composite of 4 variables: number of tender joints/28, number of swollen joints/28, CRP in mg/L and participant assessment of disease activity with visual analogue scale.
| percentage of participants | Abatacept | Adalimumab |
|---|---|---|
| The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population | 64.8 (59.5 to 70.0) | 63.4 (58.2 to 68.6) |
n=number of participants with a pre-specified local injection site reaction event, N=number of participants at risk. Proportion (%) = n/N. 12 Months includes data up to 56 days post last dose of the first 12 months Period or start of the first dose of second 12 months period.
| percentage of participants | Abatacept | Adalimumab |
|---|---|---|
| Proportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population | 3.8 (1.68 to 5.87) | 9.1 (6.03 to 12.27) |
Incidence Rate: (incidence/100 person-years) = number of participants with event \* 100 /exposure (person-years) Exposure (person-years) = the sum over all participants of the exposure per participant in the 24 months (censored at the time of first occurrence of AE) expressed in days, divided by 365.25. The 24 Month Period includes data up to 56 days post the last dose in the 24 month period. Poisson distribution used to construct the 95% CIs.
| incidence/100 person years | Abatacept | Adalimumab |
|---|---|---|
| Incidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population | 2.24 (1.20 to 3.84) | 6.38 (4.42 to 8.91) |
Plain radiographs of hands and feet taken at baseline (BL), Day 365, and Day 729. BL and Day 365 radiographs were re-read concurrent with Day 729 films by readers blinded to sequence and treatment (a second pre-specified reading campaign). SDC defined as amount of change for which anything smaller could not be reliably distinguished from random error in measurement of simultaneously read films. Non-progression defined: change from BL (Day 1, prior to dosing) in total score less than, equal to (\<=) SDC(2.2). Proportion n/m (%)=number meeting criteria (n); number analyzed (m). SDC calculated as SD/sqrt(2)\*1.96/sqrt(2)with standard deviation (SD) of paired differences of change from BL in total score between 2 readers; squared root(sqrt). mSvdHS=summary of erosion severity in 32 hand and 12 foot joints. Hand joints scored 0 to 5; foot joints 0 to 10 with 0=no erosion and higher numbers indicating greater erosion severity. BL: radiographic data within 14 days or less of first dose.
| percentage of participants | Abatacept | Adalimumab |
|---|---|---|
| Day 365 n=259, 263; m=295, 297 | 87.8 (84.1 to 91.5) | 88.6 (84.9 to 92.2) |
| Day 729 n=218, 218; m=257, 260 | 84.8 (80.4 to 89.2) | 83.8 (79.4 to 88.3) |
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post-last dose of first 12 months or start of first dose of second 12 months); denominator was overall total exposure (person-years) within this period, calculated as sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| incidence/100 person-years | Abatacept | Adalimumab |
|---|---|---|
| SAE (number with event=32, 30) | 11.06 (7.57 to 15.62) | 10.26 (6.92 to 14.65) |
| Serious Infections (number with event=7, 9) | 2.32 (0.93 to 4.79) | 2.99 (1.37 to 5.68) |
| Opportunistic infections (number with event=1, 1) | 0.33 (0.01 to 1.83) | 0.33 (0.01 to 1.85) |
| Discontinuation (number with event=44, 59) | 14.79 (10.74 to 19.85) | 20.11 (15.31 to 25.94) |
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, and all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post the last dose of the 24 Months period); denominator was overall total exposure (person-years) within this period, which was calculated as the sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express the rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| incidence/100 person-years | Abatacept | Adalimumab |
|---|---|---|
| SAE Incidence Rate (number with event=44, 54) | 13.8 (10.04 to 17.63) | 16.5 (12.45 to 20.48) |
| Serious Infections (number with event=12, 19) | 3.8 (1.68 to 5.87) | 5.8 (3.26 to 8.32) |
| Opportunistic infections (number with event=2, 5) | 0.6 (0.00 to 1.50) | 1.5 (0.20 to 2.85) |
| Discontinuation (number with event=66, 83) | 20.8 (16.30 to 25.21) | 25.3 (20.60 to 30.01) |
The induction of autoantibodies was defined as participant's antinuclear antibodies (ANA) or anti-double stranded deoxyribonucleic acid (dsDNA) converting from a negative status at baseline to a positive status at a post-baseline measurement time point (Day 365 or Day 729). Proportion (%) = n/m, where n=number of participants with positive ANA or dsDNA at a time point and m=number of participants who had negative ANA or dsDNA at baseline. Blood samples were first tested for ANA by indirect fluorescent assay using HEp-2 Cell Line Substrate, and when positive, samples were further tested for anti-dsDNA by indirect fluorescent assay using Crithidia Luciliae Substrate.
| Percentage of participants | Abatacept | Adalimumab |
|---|---|---|
| Day 365 ANA; n=12, 28; m=229, 210 | 5.2 (2.4 to 8.1) | 13.3 (8.7 to 17.9) |
| Day 365 anti-dsDNA; n=1, 29; m=299, 293 | 0.3 (0.0 to 1.0) | 9.9 (6.5 to 13.3) |
| Day 729 ANA; n=12, 24; m=190, 163 | 6.3 (2.9 to 9.8) | 14.7 (9.3 to 20.2) |
| Day 729 anti-dsDNA; n=0, 29; m=248, 237 | 0.0 (0.0 to 0.0) | 12.2 (8.1 to 16.4) |
Collected over Includes data up to 56 days post the last dose in the 24 months period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept | — | 43/318 (13.5%) | 237/318 (74.5%) |
| Adalimumab | — | 54/328 (16.5%) | 232/328 (70.7%) |
| Event | Abatacept | Adalimumab |
|---|---|---|
| PneumoniaInfections and infestations | 3/318 | 4/328 |
| Cholecystitis acuteHepatobiliary disorders | 3/318 | 0/328 |
| Urinary tract infectionInfections and infestations | 3/318 | 0/328 |
| Non-cardiac chest painGeneral disorders | 1/318 | 3/328 |
| Arthritis bacterialInfections and infestations | 0/318 | 3/328 |
| CholelithiasisHepatobiliary disorders | 2/318 | 1/328 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/318 | 0/328 |
| Chest painGeneral disorders | 2/318 | 0/328 |
| Angina pectorisCardiac disorders | 2/318 | 1/328 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 2/318 | 0/328 |
| Event | Abatacept | Adalimumab |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 64/318 | 55/328 |
| NasopharyngitisInfections and infestations | 61/318 | 57/328 |
| SinusitisInfections and infestations | 51/318 | 37/328 |
| BronchitisInfections and infestations | 49/318 | 43/328 |
| Urinary tract infectionInfections and infestations | 41/318 | 32/328 |
| Back painMusculoskeletal and connective tissue disorders | 39/318 | 39/328 |
| HeadacheNervous system disorders | 32/318 | 38/328 |
| DiarrhoeaGastrointestinal disorders | 29/318 | 23/328 |
| NauseaGastrointestinal disorders | 26/318 | 28/328 |
| RashSkin and subcutaneous tissue disorders | 13/318 | 27/328 |
All randomized and treated participants who started the 12 month period.
| Age, Continuous(years) | Abatacept | Adalimumab | Total |
|---|---|---|---|
| Mean | 51.4 ± 12.6 | 51.0 ± 12.8 | 51.2 ± 12.7 |
| Sex: Female, Male(Participants) | Abatacept | Adalimumab | Total |
|---|---|---|---|
| Female | 259 | 270 | 529 |
| Male | 59 | 58 | 117 |
| Region of Enrollment(participants) | Abatacept | Adalimumab | Total |
|---|---|---|---|
| North America | 230 | 235 | 465 |
| South America | 88 | 93 | 181 |
The record gives a start of Oct 2009, a primary completion of Oct 2011 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abatacept · Adalimumab